HUTCHMED files for AIM block admission of 43.62 million shares linked to 2026 option plan

Bulletin Express06-05 16:49

HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43.62 million ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM. Admission is expected to take effect on 11 June 2026.

The new shares will be issued from time to time upon the exercise of options granted under the 2026 Share Option Scheme, approved at the company’s 12 May 2026 annual general meeting. Once issued, the shares will be fully paid and rank pari passu with existing ordinary shares.

Following admission, HUTCHMED’s total issued share capital remains unchanged at 872.34 million ordinary shares, each carrying one voting right, with no shares held in treasury. In compliance with AIM Rule 29, the company will publish six-monthly utilisation updates and monthly statements on any change in total voting rights.

The existing block admission covering 45.77 million shares under the company’s 2015 option scheme remains in force.

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141844844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141844844","market":"us","top_or_hot":-1,"title":"HUTCHMED files for AIM block admission of 43.62 million shares linked to 2026 option plan","media":"Bulletin Express","content":"<p>HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43.62 million ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM. Admission is expected to take effect on 11 June 2026.</p>\n<p>The new shares will be issued from time to time upon the exercise of options granted under the 2026 Share Option Scheme, approved at the company’s 12 May 2026 annual general meeting. Once issued, the shares will be fully paid and rank pari passu with existing ordinary shares.</p>\n<p>Following admission, HUTCHMED’s total issued share capital remains unchanged at 872.34 million ordinary shares, each carrying one voting right, with no shares held in treasury. In compliance with AIM Rule 29, the company will publish six-monthly utilisation updates and monthly statements on any change in total voting rights.</p>\n<p>The existing block admission covering 45.77 million shares under the company’s 2015 option scheme remains in force.</p>\n<p>HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED files for AIM block admission of 43.62 million shares linked to 2026 option plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED files for AIM block admission of 43.62 million shares linked to 2026 option plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-05 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43.62 million ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM. Admission is expected to take effect on 11 June 2026.</p>\n<p>The new shares will be issued from time to time upon the exercise of options granted under the 2026 Share Option Scheme, approved at the company’s 12 May 2026 annual general meeting. Once issued, the shares will be fully paid and rank pari passu with existing ordinary shares.</p>\n<p>Following admission, HUTCHMED’s total issued share capital remains unchanged at 872.34 million ordinary shares, each carrying one voting right, with no shares held in treasury. In compliance with AIM Rule 29, the company will publish six-monthly utilisation updates and monthly statements on any change in total voting rights.</p>\n<p>The existing block admission covering 45.77 million shares under the company’s 2015 option scheme remains in force.</p>\n<p>HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1141844844","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141844844","pubTimestamp":1780649349,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43.62 million ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM. Admission...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"HUTCHMED申请AIM集体接纳与2026年期权计划相关的4362万股股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43.62 million ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM. Admission is expected to take effect on 11 June 2026.\nThe new shares will be issued from time to time upon the exercise of options granted under the 2026 Share Option Scheme, approved at the company’s 12 May 2026 annual general meeting. Once issued, the shares will be fully paid and rank pari passu with existing ordinary shares.\nFollowing admission, HUTCHMED’s total issued share capital remains unchanged at 872.34 million ordinary shares, each carrying one voting right, with no shares held in treasury. In compliance with AIM Rule 29, the company will publish six-monthly utilisation updates and monthly statements on any change in total voting rights.\nThe existing block admission covering 45.77 million shares under the company’s 2015 option scheme remains in force.\nHUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141844844","isCrawlerRequest":true}